The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Urges CMMI to Test Transparently: Coalition offers principles to guide CMS’s care innovation efforts

ACR Urges CMMI to Test Transparently: Coalition offers principles to guide CMS’s care innovation efforts

February 16, 2017 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The Center for Medicare and Medicaid Innovation (CMMI), which develops concepts for healthcare payment and service delivery, must be transparent and engaged with all stakeholders as it tests new models, according to a coalition of 30 associations.

You Might Also Like
  • Advocating for CMMI Reform, Looking Ahead to Alternative Payment Models
  • ACR Leads Coalition Response to HHS Proposed Drug Pricing Threats
  • ACR Puts Forward Principles on Patient Access to Care
Also By This Author
  • Big Data Drives New Research

On Feb. 10, the Healthcare Leaders for Accountable Innovation in Medicare Coalition, which includes the ACR, released six guiding principles it hopes the CMMI will adopt as it moves forward with testing. The CMMI develops and tests innovative healthcare models and plays an important role in the Quality Payment Program element of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The CMMI is developing Advanced Alternative Payment Models (APMs), and the ACR is currently exploring the creation of rheumatology-focused APM models.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Guiding Principles
The ACR and its coalition partners urge the CMMI to:

  1. Foster strong, scientifically valid testing of experiments prior to expansion and ensure that participation in all model tests be voluntary;
  2. Respect the role of Congress in making health policy changes, including approval of model expansions and any related changes to Medicare and Medicaid;
  3. Consistently provide transparency and meaningful stakeholder engagement as it develops, tests and expands models;
  4. Improve data sharing from these tests and release results to the public, so the impact on care quality and costs may be assessed;
  5. Strengthen beneficiary safeguards so patients are adequately educated about new demonstration tests; and
  6. Collaborate with the private sector to facilitate competitiveness and innovation as it tests new models for healthcare quality and cost efficiency of care.

“These principles will go a long way toward focusing the important work of the CMMI on appropriately scaled projects that align Medicare payment structures with our patients’ healthcare needs,” says Angus B. Worthing, MD, FACP, FACR, a practicing rheumatologist at Arthritis & Rheumatism Associates, PC, in Washington, D.C., and the chair of the ACR’s Government Affairs Committee. “The ACR supports fully transparent, innovative, data-driven ways to make healthcare more valuable and accessible to our patients.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

CMMI & Medicare Part B
The CMMI’s various initiatives include the design and study of accountable care organization models and speeding the adoption of evidence-based best practices in healthcare. However, some recent actions, such as its Medicare Part B Demonstration Project, are examples of overreach, says Dr. Worthing. The Part B Drug Payment Demonstration proposed to cut already-thin reimbursements to doctors, not to drug companies, to reduce overall spending on Part B drugs, such as biologics.

“After considerable advocacy on our part and that of a large coalition, the demonstration was not implemented. We do agree that the extremely high costs of biologics need to be addressed, but an essentially nationwide CMMI project was too broad in scope, and a foundational assumption—that there are less expensive, equally effective alternative therapies available for prescribers—was not applicable to rheumatology,” says Dr. Worthing. “We point out the opportunity to lower costs by strengthening the FDA’s ability to approve drugs in the biosimilar pipeline, which will foster competition that can drive down those prices. Meanwhile, the CMMI can be an important component for creating innovative, appropriately scaled projects that help our patients maintain access to treatments and care.”

Want to Learn More?
The Healthcare Leaders for Accountable Innovation in Medicare has created a website to provide updated information about these advocacy efforts. Also visit the ACR’s website for specific updates.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Susan Bernstein is a freelance medical journalist based in Atlanta.

Pages: 1 2 | Multi-Page

Filed Under: Legislation & Advocacy, Professional Topics Tagged With: Center for Medicare and Medicaid Innovation, CMMI, guideline principles, Healthcare Leaders for Accountable Innovation in Medicare Coalition, MACRA, Medicare Access and CHIP Reauthorization Act of 2015, Quality Payment Program

You Might Also Like:
  • Advocating for CMMI Reform, Looking Ahead to Alternative Payment Models
  • ACR Leads Coalition Response to HHS Proposed Drug Pricing Threats
  • ACR Puts Forward Principles on Patient Access to Care
  • ACR Publishes New Guide for RA Care

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.